A Phase 3, Randomized, Open-Label, Multicenter, Global Study of the Efficacy and Safety of Durvalumab (D) plus Tremelimumab (T) plus Enfortumab Vedotin (Ev) or D plus Ev for Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (Mibc) (Volga).
AuthID
P-00W-E6W
P-00W-E6W